TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01735643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interactive videogame Wii Fit Plus
Description: Use of the interactive videogame Wii Fit Plus für 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: waiting
Description: waiting for 12 weeks
Study: NCT04794660

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VIA triage test
Description: VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device.~After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment by ablative treatment
Description: Cryotherapy or Thermal Ablation are performed on the cervix.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment by ablative treatment
Description: Cryotherapy or Thermal Ablation are performed on the cervix.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposcopy
Description: Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.
Study: NCT03571074

Intervention type: OTHER
Intervention: Oxygenation
Description: Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.

Intervention type: OTHER
Intervention: Oxygenation
Description: Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.

Intervention type: OTHER
Intervention: Oxygenation
Description: Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
Study: NCT01066247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine hydrochloride; Midazolam
Description: intramuscular morphine 10 mg given 30 minutes before spinal blockade performing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
Study: NCT02260479

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preheated
Description: Skin disinfection solution is preheated in a warming cupboard
Study: NCT05884047

Intervention type: DEVICE
Group type: OTHER
Intervention: Virtual Glasses
Description: In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as Forest of Serenity, Calm Place, Happy Place, Gala 360 Travel \& Relax. Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel \& Relax is a Paris-Notre Dame museum tour video.

Intervention type: DEVICE
Group type: OTHER
Intervention: Virtual Glasses
Description: In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as Forest of Serenity, Calm Place, Happy Place, Gala 360 Travel \& Relax. Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel \& Relax is a Paris-Notre Dame museum tour video.
Study: NCT01603459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.~For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection.
Study: NCT00196716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fabrazyme (agalsidase beta)
Description: 1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
Study: NCT00916747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib, Zoledronic Acid, and Pravastatin
Description: Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.~Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.~Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily.
Study: NCT03644745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VM @ Home Usability
Description: Our primary outcome measures will be use of the coaching system features, level of daily physical activity, mood, self-efficacy, and user satisfaction. Secondary outcomes that will inform our further development and be important outcomes in subsequent trials include user adherence to their coaching goals, physical function and level of socialization. For the pilot study, we plan to assess physical function and level of socialization at baseline and at the end of 3 months. For the other outcome measures, we will be able to integrate the data collection into the VM@Home platform and coaching process.
Study: NCT04794660

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposcopy
Description: Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.
Study: NCT02525094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI9929
Description: Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
Study: NCT00663299

Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular Embolization Device
Description: The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
Study: NCT04051554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular and Proprioceptive Training
Description: Myklebust's training program (floor exercises, mat exercises, and wobble board exercises for 5 weeks)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Running, Sprinting, Agility training and Dynamic stretching for five weeks
Study: NCT01804569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: modernly developed moxibustion treatment device with safe cover on top of it.
Study: NCT02177513

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Placebo
Description: Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cannabis + Placebo
Description: Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Inhaled Cannabis
Description: Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Smoked Cannabis
Description: Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6.9% cannabis oral
Description: Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
Study: NCT03002454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc MDP Injection:neutron-bombardment
Description: Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
Study: NCT03256747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: NMES will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time application will be 60 minutes. Intensity will be adjusted individually, taking into account the patient's ability to promote the full knee extension and comfort during contractions.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NMES-placebo
Description: NMES-placebo will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time of application will be 60 minutes. Intensity will be adjusted with minimal intensity, utilized to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
Study: NCT02789410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine is administered as part of spinal anesthesia for post-operative pain relief.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
Study: NCT02335099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: ticagrelor 90 mg twice a day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill twice a day for 6 months
Study: NCT00075582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Some patients may undergo second-look surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Given IV
Study: NCT05108597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400ug misoprostol will be administered through rectal route, 1 hour before surgery to assess its effect on intra-operative blood loss during myomectomy
Study: NCT03033342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral single doses of MRX-4
Description: Oral single escalating doses of MRX-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral multiple doses of MRX-4
Description: Multiple ascending doses of MRX-4 given twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-4 co-administered with omeprazole
Description: MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral single doses of placebo
Description: Single doses of placebo to match MRX-4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral multiple doses of placebo
Description: Oral placebo given twice daily for 10 days to match the oral MRX-4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo co-administered with omeprazole
Description: Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
Study: NCT02303899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: infusion drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: oral drug
Study: NCT03984630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Fiber Intervention
Description: Intervention included weekly group-based phone counseling with a Registered Dietitian (RD) to encourage consumption of a high fiber diet (≥30 g/day). All women reported their body weight weekly.
Study: NCT02002572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation
Study: NCT01813123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RealTeen
Description: A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
Study: NCT02609685

Intervention type: OTHER
Group type: OTHER
Intervention: Active Surveillance
Description: Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
Study: NCT04376827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Participants will receive guselkumab Dose 1 via IV administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo IV at Weeks 0, 4 and 8 (that is, 3 IV doses) and placebo SC q4w from Week 12 through Week 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Participants will receive guselkumab Dose 2 via SC route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care treatment
Description: Participants will receive standard of care treatment including MMF/MPA and glucocorticoids from Week 12 through Week 48.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-care treatment
Description: Participants will receive standard of care treatment including MMF/MPA and glucocorticoids from Week 12 through Week 48.
Study: NCT04243395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pork
Description: 1 oz lean pork

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg
Description: 1 large whole egg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black beans
Description: 0.5 cups cooked black beans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: 0.5 oz almonds
Study: NCT02514668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT02899923

Intervention type: OTHER
Intervention: Data collection
Study: NCT00408590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: carcinoembryonic antigen-expressing measles virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oncolytic measles virus encoding thyroidal sodium iodide symporter

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT03633669

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fecal calprotectin
Description: Testing every 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: As per treating gastroenterologist
Study: NCT01516567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab
Description: 6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
Study: NCT02535416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Study: NCT04326764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat should be taken orally once on each scheduled day at about the same time, either with or without food. Each dose of panobinostat should be taken with a cup of water.~The capsules should be swallowed as whole. If vomiting occurs during the course of treatment, no re-dosing is allowed before the next scheduled dose. If one dose is forgotten during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next schedule treatment day. The patient should then continue treatment with the original dosing schedule.~Panobinostat will be administered at a dose of 20 mg three times weekly (TIW) every second week and will be dosed on a flat scale of mg/day and not by weight or body surface area.~Panobinostat will be dispensed as a 20 mg capsule or as two 10 mg capsules.
Study: NCT02920957

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon C
Description: contact lens
Study: NCT00272116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc and vitamin A single dose at enrollment
Description: 10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and vitamin A single dose at enrollment
Description: Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
Study: NCT00721721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Sodium Diet
Description: 3 grams of salt or 51.3 mmol of sodium per day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Sodium Diet
Description: 18 grams of salt or 307.8 mmol of sodium per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Supplementation
Description: 60 mmol potassium supplement
Study: NCT01359462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolvaptan
Description: Drug: tolvaptan~tablet, 15mg, Qd, for 7 days.
Study: NCT05173935

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous endoscopic gastrostomy
Description: Gastrostomy tube placement using an endoscopic camera inserted via the mouth into the stomach to place the tube.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiologically-inserted gastrostomy
Description: Gastrostomy tube placement using a temporary nasogastric tube placed from nose to stomach and fluoroscopy (x-rays).
Study: NCT02431390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAPAELⓇ Smart Glove digital treatment system
Description: The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Additional occupational therapy
Description: 30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
Study: NCT03753100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-energy X-ray absorbtiometry to evaluate periprosthetic bone mineral density around an uncemented stem implanted using either lateral or anterolateral approach to the hip joint
Description: The measurement will start in the area about 2 cm proximal to the greater trochanter and will stop slightly below the tip of the prosthesis. This is the baseline scan and will be carried out twice with the patient lying on the table, but with movement between each scan. This is done to calculate the CV, Coefficient of Variation. We will use the formula from Wilkinson and associates, where delta is standard deviations (SD) of the difference between the two BMD measurements for each patient. BMD has been measured at baseline, 3 and 12 months. A DXA scan is now planned at 60 months. Changes in BMD related to the 7 Gruen zones will be registered.
Study: NCT03814655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full digital workflow
Description: Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be full digital.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partially digital workflow
Description: Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be partially digital.
Study: NCT02687347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral methadone
Description: Oral methadone is the study drug